Estrogen receptor (ER) positive breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of any targeted therapy often results in resist
Additional file 6. Jupyter Notebook tumour-growth-2004.ipynb: minimal pharmacokinetic-pharmacodynamic(PK-PD)model linking that linking the dosing regimen of an anticancer agent to the tumour growth, p
Definition of tumor dynamics model parameters, reference values and corresponding literature references, and values assigned for the implementation of four virtual tumors. T1: Tumour T1, T2: Tumour T2
Platinum drugs and PARP inhibitors (“PARPis”) are considered to be effective in BRCA-associated cancers with impaired DNA repair. These agents cause stalled and collapsed replication forks and create